Biomarkers · Bone & Mineral
Bone Mineral Density T-score (DXA)
Higher values go with lower risk of death. Not measured in our NHANES panel. The curve is drawn from the published study (source below).
DXA and risk of death
Published curve higher than the NHANES fitNHANES fit higher
Risk of death relative to the curve's reference value, drawn from the published study (source below).
What studies found when this marker was changed
They describe what happened in those study groups, not a recommendation. See all catalogued interventions.
Measured changes in DXA, study by study
1 effect with a numeric size, each from one study arm: the dot is the reported change, the line its 95% interval where one was given. Green points move the marker the way lower risk of death lies; amber the other way. Study results in the groups studied, not predictions for a person.
| Type | Intervention | Reported effect | Evidence | Source |
|---|---|---|---|---|
| pharmacologic | Oral sitagliptin added to metformin for 52 weeks in women with type 2 diabetes | Total proximal femur T-score preserved (-0.02) vs decline on placebo (-0.13); between-group difference +0.11 T-score (95% CI 0.03-0.19) at 52 weeks | RCT | Barchetta I, et al. BMC Med. 2025. Effect of sitagliptin vs. placebo on bone… |
Sources
- Risk curve: Qu X 2013 (PMID 22112679): all-cause HR 1.17 (1.13-1.22) per SD decrease in BMD at all sites. Scaled to US values (NHANES).
- Qu X, Huang X, Jin F, Wang H, Hao Y, Tang T, Dai K. Bone mineral density and all-cause, cardiovascular and stroke mortality: a meta-analysis of prospective cohort studies. Int J Cardiol. 2013;166(2):385-393.
Map Bone Mineral Density T-score (DXA) against another biomarker.
Related markers: Broadband Ultrasound Attenuation (Heel) · C-Terminal Telopeptide of Type I Collagen (CTX) · Osteocalcin · Osteoprotegerin (OPG) · Parathyroid Hormone (PTH)